Submitted by Lisa Igidbashian, MSN, CRNP, Valve Program Coordinator
Lankenau Medical Center now offers MitraClip, the world’s first percutaneous mitral valve repair therapy available, providing an option for select patients with mitral valve regurgitation (MR). This procedure is indicated for primary mitral regurgitation in patients not deemed to be candidates for surgical repair or replacement.
MR is the most common type of heart valve insufficiency in the United States. Approximately 4 million people have significant mitral valve insufficiency.1 Percutaneous mitral valve repair expands the treatment options for patients suffering from the debilitating symptoms of MR.
Lankenau is one of three centers in Pennsylvania selected to perform initial post-FDA approval percutaneous mitral valve repair procedures in the region.
Clinical evidence for MitraClip therapy demonstrates: 2,3
- Positive safety profile
- Reduction in mitral regurgitation
- Favorable left ventricular remodeling
- Improvement in patient symptoms
- Reduction in hospitalizations for heart failure
With the addition of MitraClip, Lankenau’s cardiac team continues to lead the region in offering minimally invasive options for patients with valve disease. Lankenau Medical Center already offers multiple valve options, including the Edwards Sapien XT transcatheter heart valve and the CoreValve System.
1 US Census Bureau. Statistical Abstract of the US: 2006, Table 12.
2 Feldman T, Foster E, Qureshi M, et al. The EVEREST II Randomized Controlled Trial: Three Year Outcomes. Transcatheter Cardiovascular Therapeutics; October 22-26, 2012; Miami, FL.
3 Schillinger, W. ACCESS-EUROPE Phase I: A Post Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at 1 Year. ESC 2012; August 25-29, 2012; Munich, Germany.